A preclinical evaluation of the targeting of VEGF and HER2 in intraperitoneal ovarian cancer cell line models with IRDye800CW-labeled bevacizumab and trastuzumab reported specific tumor detection in vivo, suggesting its potential as a targeting moiety for image-guided surgery [37]. This evidence concerns the gene ERBB2 and ovarian cancer.